Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

ELEKTA B

EKTAb.STSE0000163628NASDAQ StockholmSESEK
Stock price
ELEKTA B
Loading chart...

Coverage

Latest articles

Elekta outlines growth strategy, revises order backlog
11 Jun 2025, 19:27EKTAb.STNASDAQ Stockholm

Elekta AB detailed its future growth prospects and the results of a proactive order review at its Investor Update in Stockholm, the company said Tuesday.

Elekta revises order backlog down by 4.9 billion Swedish krona, targets 14% EBIT margin
10 Jun 2025, 09:03EKTAb.STNASDAQ Stockholm

Elekta announced a significant adjustment to its order backlog, cancelling orders valued at 4.9 billion Swedish Krona following a proactive review aimed at improving profitability and predictability.

Elekta names Jakob Just-Bomholt as new President and CEO
9 Jun 2025, 20:29EKTAb.STNASDAQ Stockholm

Elekta has appointed Jakob Just-Bomholt as its new President and CEO, effective September 1, 2025, the medical technology firm announced.

Elekta appoints Jakob Just-Bomholt as new president and CEO
9 Jun 2025, 20:26EKTAb.STNASDAQ Stockholm

Elekta announced Monday the appointment of Jakob Just-Bomholt as its new President and Chief Executive Officer, effective September 1, 2025.

Elekta appoints Jakob Just-Bomholt as new president and CEO
9 Jun 2025, 17:06EKTAb.STNASDAQ Stockholm

Elekta has named Jakob Just-Bomholt as its new President and Chief Executive Officer, effective September 1, 2025, the company announced.

Elekta reports mixed full-year results amid R&D impairment
8 Jun 2025, 20:30EKTAb.STNASDAQ Stockholm

Swedish medical technology firm Elekta reported a net loss of 381 million Swedish Kronor for its fourth quarter, impacted by a 1.064 billion Swedish Kronor non-cash impairment from discontinued research and development projects, the company said.

  • Previous
  • 1
  • 2

Filings

Recent filings

FilingDate
Elekta changes outlook for 2019/20 and addresses challenges related to COVID-1928 Apr 2020
Interim report May-January 2019/2020 Feb 2020
Correction regarding press release: Québec to acquire advanced linear accelerators to meet growing need for advanced cancer care17 Feb 2020
Québec to acquire 12 Elekta Versa HD linear accelerators to meet growing need for advanced cancer care11 Feb 2020
Institut Jules Bordet invests in Elekta’s latest cancer treatment technology20 Jan 2020
Elekta completes its investment in ViewRay6 Dec 2019
Elekta announces collaboration with ViewRay for the advancement of MR-guided radiation therapy and investment in minority stake through a public offering2 Dec 2019
Interim report, May–October 2019/2028 Nov 2019
Elekta announces preliminary Q2 results and updated guidance for fiscal year 2019/2015 Nov 2019
Elekta’s Nomination Committee for the 2020 Annual General Meeting14 Nov 2019
Interim report, May–July 2019/2022 Aug 2019
Bulletin from Elekta's annual general meeting 201922 Aug 2019
  • Previous
  • 1
  • More pages
  • 13
Search
Company
ELEKTA B
EKTAb.STNASDAQ Stockholm
Website: Unavailable
Coverage
12
  • Next
  • 14
  • 15
  • More pages
  • 59
  • Next
  • Filings
    703